J Korean Pediatr Soc.  2003 Sep;46(9):876-882.

Myocardial Protective Effect of Cardioxane for the Myocardial Damage due to Doxorubicin

• Park HJ
• Oh JM
• Kim SH
• Lee CH
• Kim SS

Abstract

PURPOSE
To find out the myocardial protective effect of cardioxane for the myocardial damage by doxorubicin.
METHODS
Using Eighteen rabbits(2.0-3.2 kg), doxorubicin(30 mg/m2) was injected intravenously once a week in group I(12 rabbits) and cardioxane(600 mg/m2) was injected at 20-30 minutes before doxorubicin administration in group II(6 rabbits). After this, we operated on the rabbits when the total cumulative dose of doxorubicin was reached at 210, 240, 270 and 300 mg/m2 and observed the degree of myocardial damage with light and electronic microscope.
RESULTS
In group I, rabbits with less than 210 mg/m2 of total cumulative dose of doxorubicin, there was no definite myocardial damage but with 240 mg/m2, focal degenerative change was observed and with 300 mg/m2, severe degenerative change was detected with light microscopic examination. With electronic microscope, rabbits with less than 180 mg/m2 of total cumulative dose of doxorubicin in group I, there was no evidence of myocardial damage. In 210 mg/m2, focal degenerative change was detected. With 240 mg/m2, degenerative change was much more advanced and with 300 mg/m2, severe degenerative change was detected. In group II, no definite myocardial damage was observed even though the total cumulative dose of doxorubicin reached 300 mg/m2, but with 360 mg/m2, there was a focal area where myocardial fibers were somewhat decreased, but it's difficult to say whether these decrement were due to adriamycin in the electronic microscopic examination.
CONCLUSION
Cardioxane have a good protective effect for the doxorubicin induced cardiomyopathy and it will be used safely in pediatric cancer patients.

Keyword

Cardioxane; Doxorubicin; Myocardial degenerative change

MeSH Terms

Cardiomyopathies
Dexrazoxane*
Doxorubicin*
Humans
Rabbits
Doxorubicin